Victory Capital Management Inc. Has $10.57 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Victory Capital Management Inc. grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX – Get Rating) by 4.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 269,671 shares of the biopharmaceutical company’s stock after buying an additional 10,348 shares during the quarter. Victory Capital Management Inc.’s holdings in Royalty Pharma were worth $10,568,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in RPRX. Vanguard Group Inc. lifted its stake in Royalty Pharma by 7.5% in the first quarter. Vanguard Group Inc. now owns 31,860,621 shares of the biopharmaceutical company’s stock valued at $1,241,289,000 after acquiring an additional 2,224,056 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Royalty Pharma by 4.6% in the 1st quarter. BlackRock Inc. now owns 17,483,188 shares of the biopharmaceutical company’s stock valued at $681,145,000 after purchasing an additional 767,864 shares during the last quarter. State Street Corp increased its position in Royalty Pharma by 9.7% during the first quarter. State Street Corp now owns 7,762,572 shares of the biopharmaceutical company’s stock worth $302,430,000 after buying an additional 685,242 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Royalty Pharma during the first quarter worth $23,083,000. Finally, Ensign Peak Advisors Inc raised its holdings in Royalty Pharma by 590.9% during the third quarter. Ensign Peak Advisors Inc now owns 677,916 shares of the biopharmaceutical company’s stock valued at $27,239,000 after buying an additional 579,802 shares in the last quarter. Institutional investors own 55.36% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on RPRX. Tigress Financial increased their price objective on Royalty Pharma from $57.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, April 6th. StockNews.com downgraded shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, April 10th. TheStreet lowered Royalty Pharma from a “c-” rating to a “d+” rating in a report on Tuesday, February 21st. Finally, UBS Group cut their price target on Royalty Pharma from $51.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, February 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $54.00.

Insider Activity at Royalty Pharma

In related news, CEO Pablo G. Legorreta acquired 150,000 shares of the firm’s stock in a transaction on Wednesday, May 24th. The shares were bought at an average cost of $32.25 per share, with a total value of $4,837,500.00. Following the completion of the acquisition, the chief executive officer now owns 380,000 shares of the company’s stock, valued at $12,255,000. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Pablo G. Legorreta purchased 150,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The shares were acquired at an average price of $32.25 per share, with a total value of $4,837,500.00. Following the purchase, the chief executive officer now directly owns 380,000 shares in the company, valued at $12,255,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP George W. Lloyd sold 100,000 shares of the stock in a transaction on Tuesday, March 28th. The stock was sold at an average price of $37.06, for a total value of $3,706,000.00. Following the transaction, the executive vice president now owns 225,000 shares of the company’s stock, valued at $8,338,500. The disclosure for this sale can be found here. Insiders have sold a total of 1,859,926 shares of company stock valued at $61,507,766 over the last quarter. 24.86% of the stock is owned by company insiders.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX opened at $32.22 on Thursday. The firm has a market capitalization of $19.56 billion, a price-to-earnings ratio of 58.58, a PEG ratio of 0.66 and a beta of 0.42. Royalty Pharma plc has a one year low of $32.02 and a one year high of $44.66. The business has a fifty day simple moving average of $35.27 and a 200 day simple moving average of $37.93. The company has a current ratio of 2.36, a quick ratio of 2.36 and a debt-to-equity ratio of 0.62.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Friday, May 19th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date of this dividend is Thursday, May 18th. Royalty Pharma’s payout ratio is 145.45%.

About Royalty Pharma

(Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.